TALPHERA INC

Talphera’s board‑wide insider buying signals strong confidence in its non‑opioid pain drug pipeline and value‑driven upside—an insider‑approved opportunity for investors.

CEO Angotti boosts Talphera stake to 800k shares, signaling bullish outlook as nafamostat data nears—investors eye potential upside.

CEO insider buy of Tal­phera shares sparks short‑term optimism amid regulatory uncertainty and a hopeful pipeline for Niyad.

Tal Phera’s insider buying and new warrants hint at rising investor confidence as its peripheral opioid pipeline shows promising pain‑relief data and a clear path toward FDA approval and potential shareholder gains.